ArticleTranslational lung cancer research2026
A lung squamous cell carcinoma demonstrating spontaneous partial regression of the primary tumor with lymph node metastasis: a case report with analysis of the tumor immune microenvironment.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spontaneous regression (SR) of malignant tumors is a well-known but rare phenomenon in lung cancer. Previous studies have suggested that antitumor immune responses may contribute to SR. Case Description: We report the case of a 74-year-old man with a right lower lobe pulmonary nodule that demonstrated regression during observation, accompanied by mediastinal lymph node (LN) metastasis after nondiagnostic bronchoscopic and needle biopsies. Surgical resection confirmed squamous cell carcinoma with subcarinal LN metastasis. The primary tumor was largely replaced by fibrosis, with residual carcinoma cells comprising only 30% of the lesion. Immunohistochemistry (IHC) demonstrated marked infiltration of multiple T-cell subsets in the primary tumor, whereas the metastatic lesion exhibited reduced immune infiltration. Antigen-presentation-related markers, including β2-microglobulin (B2M), human leukocyte antigen-DR (HLA-DR), and programmed death-ligand 1 (PD-L1), were expressed in the primary lesion but were lost in the metastasis. Overall, the primary lesion showed dense infiltration of CD8 Conclusions: By comparing the immune microenvironments in the primary tumor and the metastatic LN, this case suggests that differences in local immune context may underlie the distinct clinical behavior of the two lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.